Clinical Trials Logo

Lung Cancer clinical trials

View clinical trials related to Lung Cancer.

Filter by:

NCT ID: NCT03837600 Completed - Lung Cancer Clinical Trials

Sputum Labeling Utilizing Synthetic Meso-Tetra (4-Carboxyphenyl) Porphyrin (TCPP) for Detection of Lung Cancer

Start date: September 22, 2016
Phase:
Study type: Observational

The primary objective of this study is optimization of the assay to discriminate between cancer cells and non-cancer cells in sputum samples by the performance of experiments that will determine methods to liquefy sputum, select proper fixatives and buffers, determine the efficacy of use of methyl-beta-cyclodextrin (MBCD) in sputum processing and determine the use of flow cytometry for high-throughput, and in the establishment of cell count and sputum cell populations in patient samples. The secondary objective of this study is comparison of the characteristics of sputum from three cohorts labeled with CyPath Lung to determine differential characteristics between samples taken from Participants who are not at high risk for lung cancer, Participants at high risk for lung cancer who are free of the disease and Participants with confirmed lung cancer.

NCT ID: NCT03820557 Completed - Lung Cancer Clinical Trials

Decision Counseling Program in Increasing Shared Decision Making and Clinical Trial Participation in Patients With Stage 0-IV Lung Cancer (Free to Breathe)

Start date: August 3, 2017
Phase: N/A
Study type: Interventional

This clinical trial studies how well the Decision Counseling Program works in increasing patient-physician shared decision making and participation in clinical trials for lung cancer patients. Decision aids help provide patients with information that may help them select a course of action related to their cancer care when more than one alternative is available. It also encourages shared decision making allowing patients and their providers to make health decisions together. Determining how patients make decisions about participating in a clinical trial may help doctors facilitate patient decision making and improve participation in lung cancer clinical trials.

NCT ID: NCT03815097 Completed - Lung Cancer Clinical Trials

Prospective Study to Evaluate Mapleson Circuit With Monitored Anesthesia Care During Endobronchial Ultrasound (EBUS) Bronchoscopy

Start date: October 1, 2014
Phase: N/A
Study type: Interventional

If the investigators can prove that the use of a mapleson circuit attached to a nasal trumpet employed during monitored anesthesia care leads to less sedation requirements, less procedure interruptions, shorter procedure duration, this would allow for to standardization of the type of anesthetic employed for EBUS at the investigators' institution and elsewhere. Less hypoxic episodes and less anesthetic requirements would benefit outcomes, lead to less recovery time and earlier discharges. Shorter procedural duration will create greater efficiency in the short procedure unit where the EBUS are performed.

NCT ID: NCT03804398 Completed - Lung Cancer Clinical Trials

Effect of Optimal Positive End-Expiratory Pressure on Oxygenation and Intrapulmonary Shunt During One-lung Ventilation

Start date: June 14, 2018
Phase: N/A
Study type: Interventional

To observe the effect of compliance guided an optimal Positive End-Expiratory Pressure(PEEP)on arterial oxygenation and intrapulmonary shunt during one-lung ventilation(OLV),and discuss the lung protective effect of optimal PEEP during one-lung ventilation.

NCT ID: NCT03794414 Completed - Lung Cancer Clinical Trials

Positive End-expiratory Pressure (PEEP) in Predicting Fluid Responsiveness in Patients Undergoing One-lung Ventilation

Start date: January 31, 2019
Phase: N/A
Study type: Interventional

The present study is to evaluate the effect of positive end-expiratory pressure (PEEP) in predicting fluid responsiveness in patients undergoing one-lung ventilation.

NCT ID: NCT03790423 Completed - Breast Cancer Clinical Trials

18F-ASIS PET/CT Imaging of Tissue Factor Expression In Patients With Primary and Metastastic Cancer

Start date: January 3, 2019
Phase: Phase 1
Study type: Interventional

The primary objective of the trial is to test the new radio tracer 18F-ASIS for PET imaging of tissue factor (TF) expression. The tracer has the potential of identifying tumors with high levels of TF expression, which is expected to correlate with tumor aggression and prognosis. Furthermore, the tracer can potentially be used as companion imaging diagnostic agent for identifying patients eligible for TF directed therapies. This is a first-in-man study to test the radio tracer in cancer patients. Safety, biodistribution and dosimetry will be evaluated by repeated PET imaging (1 hour, 2 hours and 4 hours post-injection).

NCT ID: NCT03773380 Completed - Lung Cancer Clinical Trials

Breathe Anew for Lung Cancer Survivorship

BA
Start date: January 2, 2019
Phase: Phase 1
Study type: Interventional

Survivorship programs have become an integral component of modern cancer care programs. In Canada, there has been tremendous success for survivorship programs for breast, prostate, and colorectal cancer, however lung cancer survivorship programs have not been widely developed. The complexity of the disease, high mortality, short survival times, high cost of surveillance, and patient habits have traditionally been barriers against the success of lung cancer survivorship programs. The investigator proposes a feasibility study to pilot a novel intervention titled Breathe Anew, which will aim to identify and overcome the barriers to the design and implementation of a lung cancer survivorship program. The investigator has assembled a multi-disciplinary team of experts and lung cancer survivors who will develop the Breathe Anew survivorship intervention. The intervention will be vetted using an integrated knowledge translation approach, which will involve members of the target population, primarily patients who previously underwent lung resection, to modify the intervention and ensure acceptability. After Breathe Anew has been designed, it will be tested in a pilot study of 50 patients to ensure its feasibility and determine its cost. The ultimate goal of this feasibility study is to lay the groundwork for a subsequent comparative trial to evaluate the impact of Breathe Anew on patient-important outcomes including health related quality and length of life and postoperative complications.

NCT ID: NCT03755102 Completed - Lung Cancer Clinical Trials

A Pilot Study of Dacomitinib With or Without Osimertinib for Patients With Metastatic EGFR Mutant Lung Cancers With Disease Progression on Osimertinib.

Start date: November 21, 2018
Phase: Early Phase 1
Study type: Interventional

The purpose of this study is to assess whether dacomitinib after osimertinib is effective in participants with metastatic EGR-mutant lung cancers.

NCT ID: NCT03753724 Completed - Lung Cancer Clinical Trials

IDEAL: Artificial Intelligence and Big Data for Early Lung Cancer Diagnosis Study

IDEAL
Start date: August 29, 2018
Phase:
Study type: Observational

This study aims to test the use of novel CT image analysis techniques to enable a better characterisation of small pulmonary nodules. The study will incorporate solid and predominantly solid nodules of 5-15 mm scanned using a variety of scanner types, imaging protocols and patient populations. The investigators hope that the new image processing techniques will improve the accuracy of lung nodule analysis which will in turn reduce the number of unnecessary investigations for benign nodules and may increase the accuracy of the early diagnosis of lung cancer in malignant nodules. This study aims to test this novel analysis software to subsequently allow validation.

NCT ID: NCT03750864 Completed - Lung Cancer Clinical Trials

Innovative Approach to Reduce Lung Cancer Stigma

Start date: October 27, 2018
Phase: N/A
Study type: Interventional

This is a feasibility study examining the feasibility and acceptability of a novel psychotherapy intervention on lung cancer patients who are experiencing stigma.